alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          14,663
<SECURITIES>                                         0
<RECEIVABLES>                                      766
<ALLOWANCES>                                         0
<INVENTORY>                                      1,109
<CURRENT-ASSETS>                                18,856
<PP&E>                                          24,933
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  51,169
<CURRENT-LIABILITIES>                           20,266
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          3
<COMMON>                                           373
<OTHER-SE>                                      19,508
<TOTAL-LIABILITY-AND-EQUITY>                    51,169
<SALES>                                            484
<TOTAL-REVENUES>                                 5,392
<CGS>                                                0
<TOTAL-COSTS>                                   31,518
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (864)
<INCOME-PRETAX>                               (28,427)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (28,427)
<EPS-BASIC>                                     (1.26)
<EPS-DILUTED>                                        0


</TABLE>
§ 520.863 Ethylisobutrazine. ( a ) *Specifications.* Each tablet contains either 10 milligrams or 50 milligrams of ethylisobutrazine hydrochloride.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally 2 to 5 milligrams per pound of body weight once daily.
( 2 ) *Indications for use.* As a tranquilizer.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 46 FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 19, 1997; 79 FR 28821, May 20, 2014]
<PAGE>



                                                                    EXHIBIT 99.1

    CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)
and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of
the undersigned officers of Deutsche Telekom AG (the "Company"), does hereby
certify, to such officer's knowledge, that:

     The Annual Report on Form 20-F for the fiscal year ended December 31, 2002,
of the Company fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934 and information contained in the Form 20-F
fairly presents, in all material respects, the financial condition and results
of operations of the Company.

<Table>
<S>                                                      <C>    <C>
                                                                /s/ Kai-Uwe Ricke
                                                                ---------------------------------------
                                                         Name:  Kai-Uwe Ricke
                                                         Title: Chairman of the Management Board
Date: April 17, 2003

                                                                /s/ Karl-Gerhard Eick
                                                                ---------------------------------------
                                                         Name:  Karl-Gerhard Eick
                                                         Title: Deputy Chairman of the Management Board
                                                                Finance and Controlling
Date: April 17, 2003
</Table>

     The foregoing certification is being furnished solely pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350,
Chapter 63 of Title 18, United States Code).

     A signed original of this written statement required by Section 906 has
been provided to Deutsche Telekom AG and will be retained by Deutsche Telekom AG
and furnished to the Securities and Exchange Commission or its staff upon
request.
# L_2020378DE.01002701.xml

| 12.11.2020 | DE | Amtsblatt der Europäischen Union | L 378/27 |
| --- | --- | --- | --- |

12.11.2020

DE

Amtsblatt der Europäischen Union

L 378/27

---

Berichtigung des Durchführungsbeschlusses (EU) 2019/2010 der Kommission vom 12. November 2019 über Schlussfolgerungen zu den besten verfügbaren Techniken (BVT) gemäß der Richtlinie 2010/75/ EU des Europäischen Parlaments und des Rates in Bezug auf die Abfallverbrennung

(
  Amtsblatt der Europäischen Union L 312 vom 3. Dezember 2019
  )

Seite 60, Anhang, Gleichung unter der Tabelle:

Anstatt:

„

  Image 1

  “

muss es heißen:

„

  Image 2

  “.

---
§ 522.390 Chloramphenicol. ( a ) *Specifications.* Each milliliter of solution contains 100 milligrams of chloramphenicol.
( b ) *Sponsor.* See Nos. 054771 and 069043 in § 510.600(c) of this chapter.
( c ) Conditions of use. Dogs — ( 1 ) *Amount.* 5 to 15 milligrams per pound of body weight, intramuscularly or intravenously, every 6 hours. In severe infections, use 4 to 6 hour treatment intervals the first day. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.
( 2 ) *Indications for use.* Treatment of infections of the respiratory tract, the urinary tract, and enteritis and tonsillitis caused by organisms susceptible to chloramphenicol.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.
[57 FR 37331, Aug. 18, 1992, as amended at 65 FR 45877, July 26, 2000; 78 FR 17597, Mar. 22, 2013; 79 FR 16185, Mar. 25, 2014; 81 FR 17608, Mar. 30, 2016]
Exhibit 32.1
                                                                  ------------
         Section 1350 Certifications of Principal Executive Officer and
                           Principal Financial Officer
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

         Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, the undersigned officers of 1st Independence
Financial Group, Inc. (the "Company"), hereby certify, to such officer's
knowledge, that:

         The Annual Report on Form 10-K for the year ended December 31, 2007
(the  "Report") of the Company  fully  complies  with the  requirements  of
section  13(a)  or  15(d)  of the  Securities  Exchange  Act  of  1934  and  the
information  contained in the Report fairly presents,  in all material respects,
the financial condition and results of operations of the Company.



Dated: March 31, 2008       /s/ N. William White
                                --------------------------------
                                Name:     N. William White
                                Title:    President and Chief Executive Officer
                                          (Principal Executive Officer)


                            /s/ R. Michael Wilbourn
                                --------------------------------
                                Name:     R. Michael Wilbourn
                                Title:    Executive Vice President
                                          and Chief Financial Officer
                                          (Principal Financial Officer)
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7405 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7405

To amend title 10, United States Code, to prohibit the exclusion of an 
individual from assignment to a medical personnel position of the Armed 
Forces on the basis of the amputation of the individual, and for other 
                               purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 16, 2024

  Mrs. Rodgers of Washington introduced the following bill; which was 
              referred to the Committee on Armed Services

_______________________________________________________________________

                                 A BILL

 
To amend title 10, United States Code, to prohibit the exclusion of an 
individual from assignment to a medical personnel position of the Armed 
Forces on the basis of the amputation of the individual, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hannah Cvancara Service Act''.

SEC. 2. PROHIBITION ON EXCLUSION OF INDIVIDUALS FROM ASSIGNMENT AS 
              MEDICAL PERSONNEL OF ARMED FORCES ON BASIS OF AMPUTATION.

    Chapter 49 of title 10, United States Code, is amended by adding at 
the end the following new section (and conforming the table of sections 
at the beginning of such chapter accordingly):
``Sec. 989. Prohibition on exclusion of individuals from assignment as 
              medical personnel on basis of amputation
    ``(a) Prohibition.--Neither the Secretary of Defense nor the 
Secretary concerned may prohibit the assignment of an individual to a 
medical personnel position, including by prohibiting the accession of 
such individual into the Armed Forces for such assignment, on the basis 
that the individual has an amputated limb (regardless of whether such 
amputated limb is the result of a service-connected illness or injury) 
if the individual otherwise meets such physical fitness and other 
standards as may be required for such accession.
    ``(b) Definitions.--In this section:
            ``(1) The term `medical personnel' has the meaning given 
        that term in section 115a(e) of this title.
            ``(2) The term `service-connected' has the meaning given 
        such term in section 101 of title 38.''.
                                 <all>
```
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.150 Drugs; processing, labeling, or repacking. ( a ) Except as provided by paragraphs (b) and (c) of this section, a shipment or other delivery of a drug which is, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantity at an establishment other than that where originally processed or packed, shall be exempt, during the time of introduction into and movement in interstate commerce and the time of holding in such establishment, from compliance with the labeling and packaging requirements of sections 501(b) and 502 (b), (d), (e), (f), and (g) of the act if: ( 1 ) The person who introduced such shipment or delivery into interstate commerce is the operator of the establishment where such drug is to be processed, labeled, or repacked; or
( 2 ) In case such person is not such operator, such shipment or delivery is made to such establishment under a written agreement, signed by and containing the post-office addresses of such person and such operator, and containing such specifications for the processing, labeling, or repacking, as the case may be, of such drug in such establishment as will insure, if such specifications are followed, that such drug will not be adulterated or misbranded within the meaning of the act upon completion of such processing, labeling, or repacking. Such person and such operator shall each keep a copy of such agreement until 2 years after the final shipment or delivery of such drug from such establishment, and shall make such copies available for inspection at any reasonable hour to any officer or employee of the Department who requests them.
( b ) An exemption of a shipment or other delivery of a drug under paragraph (a)(1) of this section shall, at the beginning of the act of removing such shipment or delivery, or any part thereof, from such establishment, become void ab initio if the drug comprising such shipment, delivery, or part is adulterated or misbranded within the meaning of the act when so removed.
( c ) An exemption of a shipment or other delivery of a drug under paragraph (a)(2) of this section shall become void ab initio with respect to the person who introduced such shipment or delivery into interstate commerce upon refusal by such person to make available for inspection a copy of the agreement, as required by such paragraph (a)(2) of this section.
( d ) An exemption of a shipment or other delivery of a drug under paragraph (a)(2) of this section shall expire: ( 1 ) At the beginning of the act of removing such shipment or delivery, or any part thereof, from such establishment if the drug comprising such shipment, delivery, or part is adulterated or misbranded within the meaning of the act when so removed; or
( 2 ) Upon refusal by the operator of the establishment where such drug is to be processed, labeled, or repacked, to make available for inspection a copy of the agreement, as required by such clause.
[41 FR 6911, Feb. 13, 1976, as amended at 64 FR 400, Jan. 5, 1999]
# Fourt **h Court of Appeals**

**San Antonio, Texas**

May 29, 2014

N o. 04

- 14

- 00249

- CV

IN THE INTEREST OF N.M.G ., A Child,

From the 131st Judicial District Court, Bexar County, Texas

Trial Court No. 2013

- PA

- 01311 Honorable Charles E. Montemayor, Judge Presid ing



### ORDE R

This is an appeal in a termination case, and is therefore accelerated. Appellant’s brief was due May 21, 2014, but was not filed. On May 29, 2014, appellant’s appointed counsel filed an extension of time to file the brief stating he was unaware that he was appointed to represent appellant on appeal until May 28, 2014. Accordingly, he filed a motion for extension of time to

file the brief, asking that he be permitted to file the brief on or before June 18, 2014. Given the circumstances, we GRANT appellant’s motion and ORDER appellant to file his brief in this court on or before June 18, 2014.

_________________________________ Marialyn Barnard, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said

court on this 29th day of May, 2014

.

___________________________________ Keith E. Hottle

Clerk of Court
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7222 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7222

   To amend the Internal Revenue Code of 1986 to allow expenses for 
  parents to be taken into account as medical expenses, and for other 
                               purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 5, 2024

 Mr. Buchanan (for himself and Mr. Thompson of California) introduced 
  the following bill; which was referred to the Committee on Ways and 
                                 Means

_______________________________________________________________________

                                 A BILL

 
   To amend the Internal Revenue Code of 1986 to allow expenses for 
  parents to be taken into account as medical expenses, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Lowering Costs for Caregivers Act of 
2023''.

SEC. 2. HEALTH SAVINGS ACCOUNTS.

    (a) In General.--Subparagraph (A) of section 223(d)(2) of the 
Internal Revenue Code of 1986 is amended by inserting ``, any parent of 
either such individual or such spouse'' after ``the spouse of such 
individual''.
    (b) Effective Date.--The amendment made by this section shall apply 
to amounts paid after December 31, 2023.

SEC. 3. FLEXIBLE SPENDING AND HEALTH REIMBURSEMENT ARRANGEMENTS.

    (a) In General.--Subsection (b) of section 105 of the Internal 
Revenue Code of 1986 is amended by adding at the end the following: ``A 
health flexible spending arrangement or health reimbursement 
arrangement shall not fail to be treated as meeting the requirements of 
this subsection or section 106, and no amount shall be included in 
gross income of the taxpayer, solely because, under the arrangement, 
the taxpayer may use amounts contributed to such arrangement for 
medical care (as defined in section 213(d), without regard to paragraph 
(1)(D) thereof) for a parent of the taxpayer or of the spouse of the 
taxpayer.''.
    (b) Effective Date.--The amendment made by this section shall apply 
to expenses incurred after December 31, 2023.

SEC. 4. ARCHER MSAS.

    (a) In General.--Subparagraph (A) of section 220(d)(2) of the 
Internal Revenue Code of 1986 is amended by inserting ``, any parent of 
either such individual or such spouse'' after ``the spouse of such 
individual''.
    (b) Effective Date.--The amendment made by this section shall apply 
to amounts paid after December 31, 2023.
                                 <all>
```
§ 207.57 What information must registrants submit when updating listing information and when? Registrants must review and update listing information at a minimum, as follows: ( a ) Registrants must provide listing information at the time of annual establishment registration for any drug manufactured, repacked, relabeled, or salvaged by them for commercial distribution that has not been listed previously.
( b ) Registrants must review and update their drug listing information each June and December. When doing so, registrants must: ( 1 ) ( i ) Provide listing information, in accordance with §§ 207.49, 207.53, and 207.54, for any drug manufactured, repacked, relabeled, or salvaged by them for commercial distribution that has not been previously listed;
( ii ) Submit the date that they discontinued the manufacture, repacking, relabeling or salvaging for commercial distribution of a listed drug and provide the expiration date of the last lot manufactured, repacked, relabeled, or salvaged;
( iii ) Submit the date that they resumed the manufacture, repacking, or relabeling for commercial distribution of a drug previously discontinued, and provide any required listing information not previously submitted; and
( iv ) Submit any material changes in any information previously submitted pursuant to §§ 207.49, 207.53, 207.54, or other relevant sections of this part; or
( 2 ) For each listed drug, certify that no changes subject to reporting under paragraph (b)(1)(iv) of this section have occurred if no such changes have occurred since the last review and update. If a drug is discontinued and FDA has received the information required under paragraph (b)(1)(ii) of this section, no further certifications are necessary for the discontinued drug. After initial electronic listing, registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the annual registration update under § 207.29(b) applicable to all of the registrant's listed drugs for which no changes have been made since the previous annual registration update.
( c ) Registrants are encouraged to submit listing information for every drug subject to listing under this part prior to commercial distribution and are encouraged to update listing information at the time of any change affecting information previously submitted.
#### § 26.61 Purpose of this part.

This part specifies the conditions by which each party will accept or recognize results of conformity assessment procedures, produced by the other party's conformity assessment bodies (CAB's) or authorities, in assessing conformity to the importing party's requirements, as specified on a sector-specific basis in subparts A and B of this part, and to provide for other related cooperative activities. The objective of such mutual recognition is to provide effective market access throughout the territories of the parties with regard to conformity assessment for all products covered under this part. If any obstacles to such access arise, consultations will promptly be held. In the absence of a satisfactory outcome of such consultations, the party alleging its market access has been denied may, within 90 days of such consultation, invoke its right to terminate the “Agreement on Mutual Recognition Between the United States of America and the European Community,” from which this part is derived, in accordance with § 26.80.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Transportation

###### Federal Highway Administration

# AGENCY:

Federal Highway Administration (FHWA), TxDOT.

# ACTION:

Cancellation of SH 35 EIS.

# SUMMARY:

In Vol. 68, No. 210/Thursday, October 30, 2003/Notices, FHWA issued a Notice of Intent to advise the public that an Environmental Impact Statement would be prepared for the proposed SH 35 roadway between Bellfort Road and FM 1462 in Harris and Brazoria Counties, Texas. The use of Federal funding for this project is no longer proposed and a State Environmental Impact Statement will be prepared.

# FOR FURTHER INFORMATION CONTACT:

Mr. Gregory S. Punske, Federal Highway Administration, Texas Division, 300 East 8th Street, Room 826, Austin, Texas 78701, Telephone (512) 536-5960.

Issued on: February 19, 2010.

Gregory S. Punske,

District Engineer, FHWA Texas Division.

[FR Doc. 2010-4036 Filed 3-2-10; 8:45 am]

BILLING CODE 4910-22-M